ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY) (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and ...
The number of women who sought permanent birth control via surgery increased in the wake of Roe v. Wade's overturn in 2022 Researchers saw a 51% increase in tubal ligation in four states “There was a ...
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a ...
--$12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ women’s health ...
Femasys Inc. announced the achievement of CE mark certification for the FemBloc delivery system, marking it as the first regulatory approval in the world for a non-surgical permanent birth control ...
--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical ...
ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY) (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback